ATE191345T1 - Arzneimittel zur behandlung von autoimmunerkrankungen - Google Patents

Arzneimittel zur behandlung von autoimmunerkrankungen

Info

Publication number
ATE191345T1
ATE191345T1 AT92924908T AT92924908T ATE191345T1 AT E191345 T1 ATE191345 T1 AT E191345T1 AT 92924908 T AT92924908 T AT 92924908T AT 92924908 T AT92924908 T AT 92924908T AT E191345 T1 ATE191345 T1 AT E191345T1
Authority
AT
Austria
Prior art keywords
thieno
triazolo
immunosuppression
chlorophenyl
dimethyl
Prior art date
Application number
AT92924908T
Other languages
English (en)
Inventor
Takeki Okumoto
Kenji Chiba
Yukio Hoshino
Hirotsugu Komatu
Mariko Nagasawa
Hidekazu Aratani
Michio Terasawa
Minoru Moriwaki
Original Assignee
Yoshitomi Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoshitomi Pharmaceutical filed Critical Yoshitomi Pharmaceutical
Application granted granted Critical
Publication of ATE191345T1 publication Critical patent/ATE191345T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
AT92924908T 1991-12-11 1992-12-10 Arzneimittel zur behandlung von autoimmunerkrankungen ATE191345T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP35088991 1991-12-11
JP2484892 1992-01-14
JP5438292 1992-02-04
JP12945592 1992-04-21
PCT/JP1992/001619 WO1993012117A1 (fr) 1991-12-11 1992-12-10 Agent immunosuppresseur

Publications (1)

Publication Number Publication Date
ATE191345T1 true ATE191345T1 (de) 2000-04-15

Family

ID=27458207

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924908T ATE191345T1 (de) 1991-12-11 1992-12-10 Arzneimittel zur behandlung von autoimmunerkrankungen

Country Status (8)

Country Link
US (1) US5686479A (de)
EP (1) EP0656361B1 (de)
AT (1) ATE191345T1 (de)
DE (1) DE69230891T2 (de)
DK (1) DK0656361T3 (de)
ES (1) ES2143993T3 (de)
GR (1) GR3033434T3 (de)
WO (1) WO1993012117A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692483A1 (de) * 1993-03-30 1996-01-17 Yoshitomi Pharmaceutical Industries, Ltd. Zelladhäsionsinhibitor und thienotriazoldiazepin-derivat
DK0989131T3 (da) * 1996-09-13 2003-03-03 Mitsubishi Pharma Corp Thienotriazolodiazepinforbindelser og deres medicinske anvendelse
CA2291735A1 (en) * 1997-05-27 1998-12-03 Takahiro Ogawa Israpafant-containing water-base preparations
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
US6986740B2 (en) * 1998-11-02 2006-01-17 Xantech Pharmaceuticals, Inc. Ultrasound contrast using halogenated xanthenes
PT1471054E (pt) 2002-01-11 2009-09-23 Daiichi Sankyo Co Ltd Derivado de aminoálcool ou derivado de ácido fosfónico e composição medicinal que os contém
US7910617B2 (en) 2004-02-24 2011-03-22 Sankyo Company, Limited Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2012075456A1 (en) 2010-12-02 2012-06-07 Constellation Pharmaceuticals Bromodomain inhibitors and uses thereof
EP2705039B1 (de) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomainhemmer und ihre verwendung
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2864336B1 (de) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazolazepinbromdomänenhemmer und verwendungen davon
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
ES2725928T3 (es) 2014-06-20 2019-09-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4S)-6-(4-clorofenil)-1-metil-4H-benzo[c]isoxazolo[4,5-e]azepin-4-il)acetamida

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3777541D1 (de) * 1986-11-17 1992-04-23 Yoshitomi Pharmaceutical Paf-antagonistische thienotriazoldiazepin-verbindungen und deren pharmazeutische anwendung.
US5221671A (en) * 1988-10-31 1993-06-22 Eisai Co., Ltd. Triazolo-1,4-diazepine derivatives and their use in pharmaceuticals
FI95708C (fi) * 1988-10-31 1996-03-11 Eisai Co Ltd Analogiamenetelmä 1,4-diatsepiinijohdannaisen ja sen farmaseuttisesti sopivan suolan valmistamiseksi
EP0368175A1 (de) * 1988-11-06 1990-05-16 Boehringer Ingelheim Kg 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin.
EP0387613A1 (de) * 1989-03-03 1990-09-19 Boehringer Ingelheim Kg Neue Thienodiazepine
US5212185A (en) * 1992-08-14 1993-05-18 G. D. Searle & Co. Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Also Published As

Publication number Publication date
EP0656361B1 (de) 2000-04-05
EP0656361A1 (de) 1995-06-07
DK0656361T3 (da) 2000-07-24
GR3033434T3 (en) 2000-09-29
DE69230891T2 (de) 2000-10-05
WO1993012117A1 (fr) 1993-06-24
US5686479A (en) 1997-11-11
DE69230891D1 (de) 2000-05-11
EP0656361A4 (de) 1995-01-18
ES2143993T3 (es) 2000-06-01

Similar Documents

Publication Publication Date Title
ATE191345T1 (de) Arzneimittel zur behandlung von autoimmunerkrankungen
AU704955B2 (en) Use of CGMP-phosphodiesterase inhibitors to treat impotence
Ra et al. Treadmill running and swimming increase cell proliferation in the hippocampal dentate gyrus of rats
RU98102398A (ru) Использование ингибиторов cgmp-фосфодиэстеразы для лечения импотенции
HUP9802824A2 (hu) Egy 2-metil-tieno-benzodiazepin-származék kristályformái és eljárás azok előállítására
ATE297208T1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
CA2157475A1 (en) Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
DE19931206A1 (de) Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
EP0692483A4 (de) Zelladhäsionsinhibitor und thienotriazoldiazepin-derivat
DE69206345T2 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
CA2125888A1 (en) Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty
DK0793498T3 (da) Bicykliske heterocykliske forbindelser til behandling af impotens
UA35604C2 (uk) Фармацевтична композиція з антидепресивною активністю
HUT61311A (en) Process for producing /1,2,4/triazolo/1,5-a//1,3,5/-traizine and pyrazolo/2,3-a//1,3,5/-triazine derivatives and pharmaceutical compositions comprising same as active ingredient
CA2229282A1 (en) Use of hyaluronic acid as an immunosuppressant
NZ318282A (en) Pharmaceutical formulation containing amoxycillin and clavulanate in a weight ratio of 12:1 and 20:1
DE68925270D1 (de) Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidinderivate und diese enthaltende Arzneimittel
Smythies et al. Structure-activity relationship studies on mescaline: The effect of dimethoxyphenylethylamine and N: N-dimethyl mescaline on the conditioned avoidance response in the rat
DE201678T1 (de) 3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-5,6-dihydro-5-methyl-6-oxo-4h-imidazo(1,5-a)(1,4)benzodiazepin, verfahren zu seiner herstellung und pharmazeutische zubereitungen.
HUP9901303A2 (hu) Gyógyszerkészítmény autoimmun betegségek kezelésére
DE69508551D1 (de) Verwendung von L-Carnitin und Derivaten zur Verringerung der Toxizität von Cyclosporin-A und anderer Immunosuppressiva
Jackson Jr et al. Glutamic acid modification of vincristine toxicity
Quartermain et al. 5-HT1A agonists disrupt memory of fear conditioning in mice
RU2005119174A (ru) Способ лечения инфаркта миокарда
HUT59604A (en) Process for producing pharmaceutical compositions for treating autoimmune diseases containing paf-antagonistic thieno-triazolo-1,4-diazepines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee